Patents Examined by Criares
  • Patent number: 6790855
    Abstract: Many chemical and pharmaceutical compositions are known to produce antinociceptive effects that are helpful in relieving pain and inflammation. Both opioids and local anesthetics serve an important function in providing peripheral pain relief. Topical administration of pain-relieving drugs to the periphery offers important advantages over systemic or local, non-topical administration. The present invention provides topical pharmaceutical compositions, formulated with at least one local anesthetic and at least one opioid analgesic in a topical excipient. The present invention also provides methods for relieving pain in a subject through topical administration of the pharmaceutical composition in an amount and a duration sufficient to synergistically potentiate an antinociceptive response. Synergistic potentiation of analgesia through topical administration of a local anesthetic/opioid pharmaceutical composition provides a new and improved approach to peripheral pain management.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: September 14, 2004
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Gavril Pasternak, Yuri Kolesnikov
  • Patent number: 6777424
    Abstract: The present invention provides methods and kits for treating osteoarthritis using an estrogen agonist/antagonist.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: August 17, 2004
    Assignee: Pfizer Inc.
    Inventor: Bruce H. Littman
  • Patent number: 6756401
    Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in promoting bone formation and/or preventing bone loss and lowering blood cholesterol. The compositions are comprised of an estrogen agonist/antagonist as a first active component and a statin as a second active component and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: June 29, 2004
    Assignee: Pfizer Inc.
    Inventors: Wesley W. Day, Andrew G. Lee, David D. Thompson
  • Patent number: 6756365
    Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: June 29, 2004
    Assignee: Trustees of Tufts College
    Inventor: Stuart B. Levy
  • Patent number: 6740660
    Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.
    Type: Grant
    Filed: January 31, 2002
    Date of Patent: May 25, 2004
    Assignee: Nastech Pharmaceutical Company, Inc.
    Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
  • Patent number: 6733794
    Abstract: A composition for topical analgesic and antiseptic use which consists essentially of a approximately equal proportions of alcohol, turpentine, and eucalyptus oil.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: May 11, 2004
    Inventors: Edward L. Ingram, Mary Scott
  • Patent number: 6727276
    Abstract: A method of treating tumors in a mammal, especially a human that have demonstrated resistance to oncology with taxane oncology agents is disclosed. The method is effective where the tumor has initially been unresponsive to taxane therapy or has developed resistance during the course of treatment. The method comprising the administration of an epothilone derivative selected from those represented by formula I: The subject epothilone derivatives are advantageous in addition to their enhanced potency and effectiveness against tumors that have demonstrated resistance to therapy with taxane oncology agents in that both are efficacious upon oral administration.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: April 27, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventor: Francis Y. F. Lee
  • Patent number: 6726916
    Abstract: A thickened film-forming composition comprising a film-forming polymer and, as thickener, a polysaccharide alkyl ether formed of units containing at least two different saccharide rings, each unit containing at least one hydroxyl group substituted with a saturated hydrocarbon-based alkyl chain. The polysaccharide alkyl ether preferably has a molecular weight of greater than 200,000 and is in particular a guar gum alkyl ether having a degree of substitution of from about 2 to 3, in particular 2.5. The composition can be used in particular in the cosmetics fields for keratinous materials, especially the nails.
    Type: Grant
    Filed: August 27, 1998
    Date of Patent: April 27, 2004
    Assignee: L'Oreal S.A.
    Inventor: Roland Ramin
  • Patent number: 6727278
    Abstract: Dense microspheres can be extracted and purified to substantial homogeneity from mammalian brain tissue, and used in the screening of therapies for potential effectiveness in impeding the formation of amyloid fibrils associated with Alzheimer's disease and other forms of cerebral amyloidosis. Compounds that, at in-tissue concentrations of 10−5 M or less, inhibit amyloid formation in a test animal injected intracerebrally with dense microspheres are particularly useful in inhibiting treating cerebral amyloidosis.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 27, 2004
    Assignee: DMS Pharmaceutical Inc.
    Inventor: Paul Averback
  • Patent number: 6716454
    Abstract: The therapeutic combination comprises as its associated active ingredients calcium in elemental form and at least one vitamin D. It also contains at least one dry and moist binder combined in synergistic quantity with at least one diluant, at least one binder, and at least one lubricant, at least one of said diluant and said binder being a sweetening agent. Advantageously, the ratio of calcium in elemental form to vitamin D, expressed in mg of elemental Ca per IU of vitamin D lies in the range 1 to 1.5, and preferably in the range 1.2 to 1.3.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: April 6, 2004
    Assignee: Laboratorie Innothera, Société Anonyme
    Inventors: Catherine Meignant, Eric Stenger
  • Patent number: 6716829
    Abstract: Combinations of aldosterone blockers and Cyclooxygenase-2 inhibitors useful in the treatment of inflammation are disclosed.
    Type: Grant
    Filed: July 26, 2001
    Date of Patent: April 6, 2004
    Assignee: Pharmacia Corporation
    Inventors: Ricardo Rocha, Marc Zack, Ellen McMahon, Eileen R. Blasi
  • Patent number: 6716436
    Abstract: A cosmetic composition for slimming which includes, in combination with a cosmetically acceptable excipient, at least one compound having the formula (I) where R1 is a group bound by a peptidic bond and selected from the group consisting of a hydrogen atom, a hydroxyl group, an acyl group, acyloxy group and a substituted or unsubstituted aminoacid; R2 is a group bond by a peptidic bond and selected from the group consisting of a hydroxyl group, an amine group, an alkoxy group, an alkylamine group, a silyloxy group or a substituted or unsubstituted aminoacid; and n is 3 or 4.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: April 6, 2004
    Assignee: Exsymol S.A.M.
    Inventor: Marie-Christine Seguin
  • Patent number: 6716875
    Abstract: This invention relates to compositions and methods for achieving a therapeutic effect such as lowering blood pressure and treating congestive heart failure in a mammal. More specifically, this invention relates to synergistic compositions comprising amounts of at least two therapeutic agents selected from the group consisting of a renin inhibitor, an angiotensin I converting enzyme inhibitor and an angiotensin II antagonist, which inhibitors and antagonists are present in amounts sufficient to cause synergistic therapeutic effects such as lowering blood pressure and treating congestive heart failure in a mammal.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 6, 2004
    Assignee: Pfizer Inc.
    Inventor: Anthony Andrea Fossa
  • Patent number: 6713468
    Abstract: Methods of using compounds of formula (I): their racemates, enantiomers, diastereoisomers and inorganic acid salts and organic acid salts thereof.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: March 30, 2004
    Assignee: Aventis Pharma S.A.
    Inventors: Jean-Claude Hardy, Jean Bouquerel, Patrick Nemecek, Jean-Claude Aloup, Serge Mignani, Jean-François Peyronel
  • Patent number: 6713057
    Abstract: Compositions and methods are provided for modulating serum cholesterol in a subject mammal. In one aspect, the invention features novel anti-lipemic drugs that include at least one identified effector of the Low Density Lipoprotein (LDL) receptor and at least one identified serum cholesterol inhibitor. In a particular aspect, the drugs include one identified sphingolipid or protein modifying same linked to one identified serum cholesterol inhibitor. Additionally provided are methods for identifying anti-lipemic drugs capable of modulating the LDL receptor and specifically SREBP-1 maturation, including assays designed to identify pharmacological drugs capable of stabilizing or reducing serum cholesterol levels in a mammal and particularly a human patient.
    Type: Grant
    Filed: February 23, 2000
    Date of Patent: March 30, 2004
    Assignee: The Johns Hopkins University
    Inventor: Subroto Chatterjee
  • Patent number: 6706272
    Abstract: A method for denaturing allergens with an effective amount of a rare earth metal salt.
    Type: Grant
    Filed: March 6, 2001
    Date of Patent: March 16, 2004
    Assignees: Shinto Fine Co., Ltd., Sumitomo Chemical Co., Ltd.
    Inventors: Keiichiro Inui, Mariko Mikame
  • Patent number: 6703008
    Abstract: Disclosed are aerosol hair spray compositions which comprise a first and a second silicone-grafted copolymer, wherein the copolymers exhibit a dichotomous viscosity behavior which results in superior hold and excellent hair feel benefits, and a method of styling hair comprising applying to the hair an effective amount of the above composition. The aerosol hair spray compositions comprise: (A) from about 0.
    Type: Grant
    Filed: March 5, 1999
    Date of Patent: March 9, 2004
    Assignee: The Procter & Gamble Company
    Inventors: Jose Antonio Carballada, Thomas Allen Hutchins
  • Patent number: 6703030
    Abstract: A composition for the treatment of skin consists essentially of a carboxylated, acidic amino acid obtained by acidifying an acidic amino acid with a carboxylic acid. The resultant material, which is also referred to as a tricarboxylic acid or an amino fruit acid, has significant benefit for the treatment of a number of skin conditions. In addition, the composition of the present invention is very noncaustic to skin, even when employed at a pH as low as 0.5. Also disclosed herein are therapeutic methods and compositions which employ the carboxylated acidic amino acids.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: March 9, 2004
    Inventor: Marvin E. Klein
  • Patent number: 6699850
    Abstract: The present invention relates to oral compositions and methods for inhibiting bone resoprtion in a mammal while counteracting the occurrence of potentially adverse gastrointestinal effects. The compositions useful herein comprise the combination of a pharmaceutically effective amount of a nitrogen-containing bisphosphonate or a pharmaceutically-acceptable salt thereof and a pharmaceutically effective amount of an isoprenoid compound.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: March 2, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Alfred A. Reszka, Edward S. Scolnick
  • Patent number: 6699847
    Abstract: Long-acting antiparasitic formulations of doramectin, suitable for injection, are described herein.
    Type: Grant
    Filed: November 7, 2001
    Date of Patent: March 2, 2004
    Assignee: Pfizer Inc.
    Inventors: Stephen Richard Wicks, Timothy Michael Lukas, Valerie Denise Harding, Snezana Milojevic